
Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAFV600E mutation and its possible molecular mechanism
Keywords: ادرار نوع پلاسمینوژن فعال; Urinary-type plasminogen activator; Papillary thyroid cancer; BRAF; ERK1/2; MEK inhibitor